This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday evening at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full-text searching of over 9,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]
A. Milestones :: Perspectives :: Featured Journal Content
B. Emergencies
C. WHO; CDC [U.S., Africa, China]
D. Announcements
E. Journal Watch
F. Media Watch
EMERGENCIES

Coronavirus [COVID-19]
Public Health Emergency of International Concern (PHEIC)

WHO - Situation report - 145
Coronavirus disease 2019 (COVID-19)  13 June 2020
Confirmed cases :: 7,553,182
Confirmed deaths :: 423,349
Countries, areas or territories with cases :: 216

Highlights
As of 13 June 10am (CEST), Chinese authorities reported to WHO 12 new confirmed cases, among them 6 in Beijing. After 10am (CEST), Chinese authorities reported additional information about an ongoing investigation of further cases in Beijing. Information about the investigation in Beijing will be made available separately and additional cases reported in subsequent Situation Reports.

:: Daily WHO situation reports here: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

WHO Director-General's opening remarks at the media briefing on COVID-19 - 12 June 2020
12 June 2020

...As the pandemic accelerates in low- and middle-income countries, WHO is especially concerned about its impact on people who already struggle to access health services – often women, children and adolescents.

The indirect effects of COVID-19 on these groups may be greater than the number of deaths due to the virus itself.

Because the pandemic has overwhelmed health systems in many places, women may have a heightened risk of dying from complications of pregnancy and childbirth.

WHO has developed guidance for health facilities and community activities on maintaining essential services, including for women, newborns, children and adolescents.

This includes ensuring women and children can use services with appropriate infection prevention and control measures, and respectful maternal and newborn care.
WHO has also carefully investigated the risks of women transmitting COVID-19 to their babies during breastfeeding.

We know that children are at relatively low-risk of COVID-19, but are at high risk of numerous other diseases and conditions that breastfeeding prevents.

Based on the available evidence, WHO’s advice is that the benefits of breastfeeding outweigh any potential risks of transmission of COVID-19...

---

**Emergencies**

**Ebola – DRC+**

*Public Health Emergency of International Concern (PHEIC)*

**No link between two ongoing Ebola outbreaks in the Democratic Republic of the Congo - WHO**

09 June 2020

Kinshasa/Brazzaville – New genetic sequence analysis by the Democratic Republic of the Congo’s (DRC) National Institute of Biomedical Research (INRB) has found that the newly-identified Ebola virus circulating in the Equateur Province in western DRC is different from the one which has infected more than 3400 people in the eastern part of the country.

The DRC’s 11th Ebola outbreak was announced on 1 June 2020 after a cluster of cases was detected in the Mbandaka area of Equateur Province. The INRB genetic sequencing analysis also found that the virus in the latest outbreak is distinct from the previous one that hit the same region in 2018. The investigation is ongoing to determine the source of the new outbreak, but it is likely that it originated from an animal source.

“We are not surprised to find no link between the current outbreak in Mbandaka and the two previous ones. The ongoing Ebola outbreaks are far apart and there is a flight ban in place due to COVID-19,” said Dr Matshidiso Moeti, World Health Organization (WHO) Regional Director for Africa. “National health authorities supported by WHO and partners have led an effective response against Ebola in eastern DRC despite huge challenges. We expect the same national expertise will be leveraged to overcome the current outbreak in Mbandaka.”

WHO has more than 20 staff on the ground supporting the Ministry of Health and partners responding to the outbreak in Mbandaka and the rural community of Bikoro. Additional staff will arrive this week to support the Ministry of Health in containing the outbreak. WHO has worked with the DRC Ministry of Health, Africa Centres for Disease Control and Prevention, the Red Cross Movement, UNICEF and other partners over the past two years to strengthen capacity to respond to Ebola outbreaks in the DRC.

“Ebola is endemic in animal reservoirs in the DRC, so it was expected that new cases would emerge,” said Dr Moeti. “While the new Ebola outbreak in Mbandaka represents a challenge, it’s one we are ready to tackle. With each experience we respond faster and more effectively.”
Together with the Ministry of Health and partners, WHO has deployed vaccinators to the affected areas. More than 600 people have been vaccinated in Mbandaka and Wangata health zones...

**Ebola Outbreak in DRC 96: 10 June 2020**

*Excerpts*

**Situation Update**
The Ebola virus disease (EVD) outbreak in Equateur Province, Democratic Republic of the Congo, continues since its declaration on 1 June 2020 by the Ministry of Health. Since our last situation report on 2 June 2020 (External Situation report 95), four additional confirmed EVD cases and four deaths have been reported. As of 8 June 2020, a total of 12 EVD cases (9 confirmed and 3 probable), including eight deaths (case fatality ratio 66.7%), have been reported from six health areas in three health zones. Of the eight deaths, four occurred in the community. The case fatality ratio among confirmed cases is 55.6% (5 deaths/9 confirmed cases). Two health workers are among the confirmed cases since the start of the outbreak, 18.2% of all cases. Of the four confirmed cases still alive, two are under treatment in the Ebola treatment centre and two are in the community...

**Conclusions**
The new outbreak of EVD in Equateur Province comes in the context of a country already burdened with a long-standing EVD outbreak in North Kivu and Ituri, the COVID-19 outbreak (affecting mainly Kinshasa), an ongoing measles outbreak and a complex humanitarian crisis.

Mbandaka is a large town with a population of 1.2 million people with air and river links to Kinshasa and Boende, increasing the risk of localised spread. The risk of disruption to surveillance and routine public health activities as a result of the COVID-19 response will potentially harm the country’s ability to rapidly contain the re-emergence of EVD. Public health measures, particularly a strong and robust surveillance system, required to detect, isolate and treat new suspected cases as early as possible is required to break any new chains of transmission, along with full community engagement with response measures.

Investigations into the origin of the last cluster of cases in Beni Health Zone are ongoing. Maintaining a robust surveillance system in order to detect, isolate, test and treat new suspected cases as early as possible remains crucial. Continued coordination, communication among partners, authorities and affected communities along with EVD survivor advocacy remain essential in this response.

::::
:::

**Emergencies**

**POLIO**
*Public Health Emergency of International Concern (PHEIC)*

**Polio this week as of 09 June 2020**

*Summary of new viruses this week (AFP cases and ES positives):*
:: **Pakistan**: one WPV1 case and 20 positive environmental samples
Côte d'Ivoire: five cVDPV2 positive environmental samples

GPEI welcomes the strong commitment of partners at Global Vaccine Summit
US$ 8.8 billion pledged to fund immunization through Gavi, the Vaccine Alliance.
09/06/2020

On 4 June 2020, the UK Government hosted Gavi’s third donor pledging conference, the Global Vaccine Summit, to mobilize at least US$ 7.4 billion to protect the next generation with vaccines, reduce disease inequality and create a healthier, safer and more prosperous world. Responding to this unique call for global solidarity, leaders from donor countries and the private sector made unprecedented commitments of US$ 8.8 billion in order to save up to 8 million lives.

Since 2019, the Global Polio Eradication Initiative (GPEI) has strengthened its collaboration with Gavi, inviting Gavi to become the sixth core partner of the GPEI. While the GPEI will continue its focus on interrupting virus transmission and eradicating polio through immunization campaigns using the oral polio vaccine (OPV), Gavi’s support for the inactivated polio vaccine (IPV) at an estimated cost of US$ 800 million during its 2021-25 strategic period represents the insurance policy for the success of the Polio Endgame Strategy...

::: WHO Grade 3 Emergencies [to 13 June 2020]
Democratic Republic of the Congo:
:: No link between two ongoing Ebola outbreaks in the Democratic Republic of the Congo 9 June 2020
:: Ebola Outbreak in DRC 96: 10 June 2020
[See Ebola above for detail]

Nigeria - No new digest announcements identified
Somalia - No new digest announcements identified
South Sudan - No new digest announcements identified
Syrian Arab Republic - No new digest announcements identified
Yemen - No new digest announcements identified

::: WHO Grade 2 Emergencies [to 13 June 2020]
Burkina Faso [in French]
:: Riposte au COVID-19 : l’OMS renforce les capacités et la biosécurité des laboratoire...
12 juin 2020

Sudan
:: Training health workers to fight COVID-19 in Sudan 28 May 2020

Angola - No new digest announcements identified
Afghanistan - No new digest announcements identified
Burundi - No new digest announcements identified
Cameroon - No new digest announcements identified
Central African Republic - No new digest announcements identified
Ethiopia - No new digest announcements identified
Iraq - No new digest announcements identified
Libya - No new digest announcements identified
Malawi - No new digest announcements identified
Measles in Europe - No new digest announcements identified
MERS-CoV - No new digest announcements identified
Myanmar - No new digest announcements identified
Niger - No new digest announcements identified
occupied Palestinian territory - No new digest announcements identified
Ukraine - No new digest announcements identified
Zimbabwe - No new digest announcements identified

WHO Grade 1 Emergencies [to 13 June 2020]
Chad - No new digest announcements identified
Djibouti - Page not responding at inquiry
Kenya - No new digest announcements identified
Mali - No new digest announcements identified
Namibia - viral hepatitis - No new digest announcements identified
Tanzania - No new digest announcements identified

UN OCHA – L3 Emergencies
The UN and its humanitarian partners are currently responding to three 'L3' emergencies. This is the global humanitarian system’s classification for the response to the most severe, large-scale humanitarian crises.

Syrian Arab Republic
:: Recent Developments in Northwest Syria - Situation Report No. 15 - As of 12 June 2020
HIGHLIGHTS
:: The Syrian Pound has halved in value since the beginning of May, pushing prices of basic necessities to record highs and further out of reach for people in northwest Syria.
:: Renewed displacement has been reported from some parts of southern Idleb governorate and northern Hama governorate following hostilities in the area.
:: No laboratory confirmed COVID-19 cases identified in northwest Syria to date.
Efforts remain focused on awareness raising and measures to mitigate an outbreak, with preparation for an effective response in the event of any cases.
:: Major humanitarian needs persist across all sectors. Due to the pressures of COVID-19 mitigation measures and the economic deterioration, there are increasing reports of gender-based protection issues such as short-term marriages, domestic violence, divorces and forced abortions.

Yemen - No new digest announcements identified
UN OCHA – Corporate Emergencies
When the USG/ERC declares a Corporate Emergency Response, all OCHA offices, branches and sections provide their full support to response activities both at HQ and in the field.

CYCLONE IDAI and Kenneth
:: 11 June 2020 Zimbabwe Situation Report, 11 June 2020

EBOLA OUTBREAK IN THE DRC - No new digest announcements identified

WHO & Regional Offices [to 13 June 2020]

Weekly Epidemiological Record, 5 June 2020, vol. 95, 23/24 (pp. 257–264)
Fast-tracking WHO’s COVID-19 technical guidance to training for the frontline

WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region AFRO
:: Africa records over 200 000 COVID-19 cases 11 June 2020
   COVID-19 continues to spread in Africa since the virus was first detected on the continent in mid-February 2020. More than 200 000 cases have been confirmed so far, with over 5600 deaths. The pandemic is accelerating – it took 98 days to reach 100 000 cases and only 19 days to move to 200 000 cases.
:: No link between two ongoing Ebola outbreaks in the Democratic Republic of the Congo 09 June 2020

WHO Region of the Americas PAHO
No new digest content identified.

WHO South-East Asia Region SEARO
:: India elected chair of WHO’s Executive Board 22 May 2020

WHO European Region EURO
:: WHO/Europe encourages health workers to ask “why?” 09-06-2020
:: COVID-19: WHO coordinates large-scale response operation in Tajikistan 09-06-2020

WHO Eastern Mediterranean Region EMRO
Website not responding at inquiry

WHO Western Pacific Region
No new digest content identified.
... Thank you all for joining us today for this briefing to update you on the CDC’s COVID-19 response. We are joined by director Dr. Robert Redfield and CDC’s incident manager Dr. Jay Butler. Dr. Redfield will give opening remarks and Dr. Butler will discuss an MMWR being released later today as well as suggestions on how to navigate daily life as communities reopen.

**MMWR News Synopsis Friday, June 12, 2020**

Trends in Pneumoconiosis Deaths — United States, 1999–2018


Knowledge and Practices Regarding Safe Household Cleaning and Disinfection for COVID-19 Prevention — United States, May 2020 (Early release June 5, 2020)

First Reported Cases of SARS-CoV-2 Infection in Companion Animals — New York, March–April 2020 (Early release June 8, 2020)

SARS-CoV-2 Infections and Serologic Responses from a Sample of U.S. Navy Service Members — USS Theodore Roosevelt, April 2020 (Early release June 9, 2020)

---

**Africa CDC**  [to 13 June 2020]

http://www.africacdc.org/  

**News**  

Outbreak Brief 21: COVID-19 Pandemic — 9 June 2020

...As of 9 am EAT 9 June 2020, a total of 196,254 COVID-19 cases and 5,341 (CFR: 2.7%) deaths have been reported in 54 African countries. This is about 2.8% of all cases reported globally. Since the last brief (2 June 2020), 43,812 new COVID-19 cases have been reported, which is a 29% increase in new cases reported compared to what was reported in the previous week (26 May to 2 June 2020)...  

---

**China CDC**

http://www.chinacdc.cn/en/  

*No new digest content identified.*
June 13: Daily briefing on novel coronavirus cases in China
On June 12, 31 provincial-level regions on the Chinese mainland as well as the Xinjiang Production and Construction Corps reported 11 new cases of confirmed infections, no new cases of suspected infections, and no deaths

Xi hails strengthened ties in pandemic fight
2020-06-12

Beijing CDC: proper use of face masks still necessary
2020-06-12

Beijing reports new case after more than 50 days
2020-06-12

China donates more medical supplies to Lebanon to fight COVID-19
2020-06-12

Announcements

Paul G. Allen Frontiers Group [to 13 June 2020]

BARDA [to 13 June 2020]
https://www.phe.gov/about/barda/Pages/default.aspx
June 11, 2020:
BARDA, Snapdragon Chemistry Inc., demonstrate deployable domestic manufacturing technology for COVID-19 vaccine component

BMGF - Gates Foundation [to 13 June 2020]
http://www.gatesfoundation.org/News/Press-Releases
JUNE 11, 2020
Bill & Melinda Gates Foundation Appoints President of Gender Equality
SEATTLE, June 11, 2020 – Today the Bill & Melinda Gates Foundation named Anita Zaidi, currently director, Vaccine Development & Surveillance (VDS) and Enteric & Diarrheal Diseases (EDD), as the first president of Gender Equality. In this new role, Anita will oversee a division comprised of the foundation’s Gender Equality program team and Gender Program Advocacy and Communications team. She will also take on responsibility for the foundation’s broader gender integration agenda, working with and across all program teams to ensure gender is
being incorporated in a smart, thoughtful way to increase impact. Anita will report directly to CEO Mark Suzman and will join the Executive Leadership Team (ELT). She will assume her new role effective November 2, 2020.

JUNE 10, 2020
Changing the National Conversation About Poverty and Economic Mobility
28 organizations from 18 states and D.C. receive $100,000 Grand Challenge Grants, Sponsored by a Group of 8 Philanthropic Partners

Bill & Melinda Gates Medical Research Institute  [to 13 June 2020]
https://www.gatesmri.org/
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.

CARB-X  [to 13 June 2020]
https://carb-x.org/
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations  [to 13 June 2020]
http://cepi.net/
Latest News
Greece announces $1.6 million funding to CEPI to support COVID-19 vaccine development
The donation, first announced by Prime Minister of Greece Kyriakos Mitsotakis on 4 May, will contribute to CEPI’s efforts to advance the development of a safe, effective and globally accessible...
COVID-19
09 Jun 2020

Clinton Health Access Initiative, Inc. (CHAI)  [to 13 June 2020]
https://clintonhealthaccess.org/
No new digest content identified.

EDCTP  [to 13 June 2020]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.

Latest news
09 June 2020

**WHO AVAREF survey highlights EDCTP’s role in supporting ethical and regulatory oversight in Africa**

In April 2020, the African Vaccine Regulatory Forum (AVAREF) conducted a digital survey of the state of regulatory activities and ethical review in Africa. On 21 May 2020, the results were presented at a webinar organised by WHO AFRO through the AVAREF Secretariat, which was attended by approximately 125 partners of AVAREF including EDCTP. The survey focused on AVAREF’s joint review process. The results highlight EDCTP’s role in strengthening the capacity for ethics review in African countries, including the use of online platforms...

---

**Emory Vaccine Center**  [to 13 June 2020]

http://www.vaccines.emory.edu/

*No new digest content identified.*

---

**European Medicines Agency**  [to 13 June 2020]


*News & Press Releases*

**Press release: Highlights of Management Board: June 2020 meeting**

MB, Last updated: 12/06/2020

**News: Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 June 2020**

PRAC, Last updated: 12/06/2020

**Press release: Latest data support continued use of ACE inhibitors and ARB medicines during COVID-19 pandemic**

Last updated: 09/06/2020

**Press release: EU actions to support availability of medicines during COVID-19 pandemic – update #7**

Last updated: 08/06/2020

**Press release: EMA receives application for conditional authorisation of first COVID-19 treatment in the EU**

Last updated: 08/06/2020

**News: Patients’ and healthcare professionals’ organisations updated on EMA’s response to COVID-19**

Last updated: 04/06/2020

---

**European Vaccine Initiative**  [to 13 June 2020]
FDA [to 13 June 2020]
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm
Press Announcements
June 12, 2020 - Coronavirus (COVID-19) Update: Daily Roundup June 12, 2020
June 12, 2020 - FDA Approves Drug to Treat Infants and Children with HIV
June 10, 2020 - Coronavirus (COVID-19) Update: Daily Roundup June 10, 2020
June 8, 2020 - Coronavirus (COVID-19) Update: Daily Roundup June 8, 2020
June 7, 2020 - Coronavirus (COVID-19) Update: FDA Reissues Emergency Use Authorizations Revising Which Types of Respirators Can Be Decontaminated for Reuse

Fondation Merieux [to 13 June 2020]
http://www.fondation-merieux.org/
News, Events
No new digest content identified.

Gavi [to 13 June 2020]
https://www.gavi.org/
News releases
No new digest content identified.

GHIT Fund [to 13 June 2020]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.

Global Fund [to 13 June 2020]
Voices

In Kenya, A Chance to See Communities Confront COVID-19
09 June 2020

Updates

43rd Board Meeting Documents
09 June 2020

Hilleman Laboratories  [to 13 June 2020]
http://www.hillemanlabs.org/
No new digest content identified.

Human Vaccines Project  [to 13 June 2020]
http://www.humanvaccinesproject.org/media/press-releases/
No new digest content identified.

IAVI  [to 13 June 2020]
https://www.iavi.org/newsroom
Press Releases
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases
Norway contributes NOK 2 billion to IFFIm
The pledge will back Vaccine Bonds, funding CEPI’s COVID-19 programme
London, 12 June 2020 – The Kingdom of Norway has committed NOK 2 billion (approximately US$ 200 million) to the International Finance Facility for Immunisation (IFFIm) to issue Vaccine Bonds that will expedite funding through Gavi...

IFRC  [to 13 June 2020]
Selected Press Releases, Announcements
No new digest content identified.

**IVAC** [to 13 June 2020]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates

**Webinar: How will a COVID-19 Vaccine be Delivered?**
June 2020
Register: The International Vaccine Access Center (IVAC) on June 17, 2020 at 1pm ET will host a 60-minute webinar, “How will a COVID-19 Vaccine be Delivered?”. Description: When a COVID-19 vaccine becomes available, it will effectively stop disease transmission only if it reaches the people who need it. Many decisions go into developing a strategy […]

**IVI** [to 13 June 2020]
http://www.ivi.int/
Selected IVI News & Announcements
No new digest content identified.

**JEE Alliance** [to 13 June 2020]
https://www.jeealliance.org/
Selected News and Events
No new digest content identified.

**MSF/Médecins Sans Frontières** [to 13 June 2020]
http://www.msf.org/
Latest [Selected Announcements]
**Coronavirus COVID-19 pandemic**

**Caring for COVID-19 patients in Tegucigalpa**
Project Update 13 Jun 2020

*El Salvador*
**Tropical Storm Amanda is “the last straw” for families in El Salvador amid COVI...**
Project Update 11 Jun 2020

**Coronavirus COVID-19 pandemic**

**“COVID-19 has brought suffering to people everywhere, but its impact...**
Speech 10 Jun 2020

**Afghanistan**
**“As midwives in Afghanistan, we are the silent leaders of our count...**
Voices from the Field 10 Jun 2020

**Coronavirus COVID-19 pandemic**
“COVID-19 has made the health system’s collapse complete” in Yemen
Project Update 10 Jun 2020

DRC Ebola outbreaks
Crisis update - June 2020
Crisis Update 9 Jun 2020

National Vaccine Program Office - U.S. HHS [to 13 June 2020]
https://www.hhs.gov/vaccines/about/index.html

NVAC 2020 Meetings
September 23-24, 2020 Meeting (Virtual)

NIH [to 13 June 2020]
Selected News Releases
Brain cells can harbor and spread HIV virus to the body
June 11, 2020 — NIH-funded study highlights the importance of addressing the brain in HIV cure strategies.

NIH researchers identify key genomic features that could differentiate SARS-CoV-2 from other coronaviruses that cause less severe disease
June 11, 2020 — Research could be a crucial step in helping scientists develop approaches to predict severity of future coronavirus disease outbreaks.

NIH-funded study to evaluate drugs prescribed to children with COVID-19
June 10, 2020 — Researchers will assess dosage, metabolism and other properties not yet determined in children.

PATH [to 13 June 2020]
https://www.path.org/media-center/
Selected Announcements
Racism is a centuries-long public health crisis that demands a public health response.
June 2, 2020 by PATH

Sabin Vaccine Institute [to 13 June 2020]
http://www.sabin.org/updates/pressreleases
Statements and Press Releases
Our Commitment to Anti-Racism
Saturday, June 6, 2020
In our strongest and most unified voice, the Sabin Vaccine Institute condemns racism. Dr. Albert Sabin was a great scientist, and importantly his work led him to fight for equality so that all children everywhere – regardless of race, religion, nationality, gender or socioeconomic status – received his lifesaving polio vaccine.
**UNAIDS** [to 13 June 2020]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
12 June 2020
**New HIV community group in Guinea fighting COVID-19**

11 June 2020
**Five UNAIDS country directors taking the lead in the COVID-19 response**

10 June 2020
**Peer consultants helping the AIDS response in Kyrgyzstan**

8 June 2020
**New HIV infections differ by sex and by region**

8 June 2020
**Targeting sex workers is not the answer**

---

**UNICEF** [to 13 June 2020]
https://www.unicef.org/media/press-releases
Selected Press releases/Announcements

Press release
**Geneva Palais briefing note on the humanitarian situation for children in Yemen**
This is a summary of what was said by Marixie Mercado, UNICEF spokesperson in Geneva – to whom quoted text may be attributed – at today’s press briefing at the Palais des Nations in Geneva.
12/06/2020

Press release
**COVID-19 may push millions more children into child labour – ILO and UNICEF**
Child labour down by 94 million since 2000, a gain now under threat
11/06/2020

Press release
**Millie Bobby Brown and Sofia Carson join United Nations Deputy Secretary-General Amina Mohammed and UNICEF Executive Director Henrietta Fore in World’s Largest Lesson Live, encouraging teens to reimagine the world post-COVID**
10/06/2020

Press release
**New UNICEF, NBIM guidance to help businesses prioritize child rights in global supply chains**
As the economic fallout of the COVID-19 pandemic threatens livelihoods across the globe, newly released guidance supports companies to improve their impact on children in the garment and footwear supply chain
Unitaid  [to 13 June 2020]
https://unitaid.org/
Featured News
No new digest content identified.

Vaccination Acceptance Research Network (VARN)  [to 13 June 2020]
https://vaccineacceptance.org/news.html#header1-2r
Announcements
No new digest content identified.

Vaccine Confidence Project  [to 13 June 2020]
http://www.vaccineconfidence.org/
Latest News & Archive
The misinformation circulating in Africa about Covid-19
10 Jun 2020

Vaccine Education Center – Children’s Hospital of Philadelphia  [to 13 June 2020]
http://www.chop.edu/centers-programs/vaccine-education-center
No new digest content identified.

Wellcome Trust  [to 13 June 2020]
https://wellcome.ac.uk/news
No new digest content identified.

The Wistar Institute  [to 13 June 2020]
No new digest content identified.

WFPHA: World Federation of Public Health Associations  [to 13 June 2020]
https://www.wfpha.org/
Latest News
WFPHA Press Release: 54th General Assembly
Thursday, 11 June 2020
This year, General Assembly was very special: first time ever online and everyone behind a screen. This has never happened in the history of our...

World Organisation for Animal Health (OIE)  [to 13 June 2020]
The OIE Working Group on Antimicrobial Resistance: Providing guidance and establishing priorities during its first year

Paris, 12 June 2020 - The Working Group on AMR is focused on assisting in the implementation of the OIE Strategy on AMR and the Prudent and Responsible Use of Antimicrobials, providing guidance, establishing priorities, addressing recommendations to maintain and develop the OIE International Standards related to AMR, assisting in the development of the OIE Antimicrobial Use database and supporting OIE Member Countries in developing communication activities and National Action Plans relating to AMR. The Working Group on AMR will also support the implementation of the recommendations of the 2nd OIE Global Conference on AMR and Prudent Use of Antimicrobials in Animals...

:::

ARM [Alliance for Regenerative Medicine] [to 13 June 2020]
Press Releases
ARM Statement on Racial Inequality & Injustice
June 5, 2020

BIO [to 13 June 2020]
Press Releases
New Report Analyzes Bioscience Industry’s Impact on Economy & Global Pandemic
June 8, 2020

The Biotechnology Innovation Organization (BIO) today released new data on the bioscience industry in the United States. The new report, The Bioscience Economy: Propelling Life-Saving Treatments, Supporting State & Local Communities,...

DCVMN – Developing Country Vaccine Manufacturers Network [to 13 June 2020]
http://www.dcvmn.org/
News
DCVMN members’ commitments on Cholera, Typhoid and HPV vaccines supply for Gavi eligible countries
04th June 2020

IFPMA [to 13 June 2020]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
Global Pharma Body Names New Communications Director
08 June 2020

ICBA – International Council of Biotechnology Associations [to 13 June 2020]
PhRMA  [to 13 June 2020]
http://www.phrma.org/
Selected Press Releases, Statements
Stakeholders raise concerns with proposed drastic changes to the pharmaceutical supply chain
Nicole Longo  |  June 11, 2020

As we work to combat the current global pandemic, it is especially critical to maintain the stability of our global manufacturing supply chain. Unfortunately, recent policy proposals that would mandate drastic changes to pharmaceutical manufacturing supply chains underestimate the significant time, resources and other feasibility challenges and complexities involved. Proponents of these proposals also ignore the strength of a geographically diverse global supply chain...

Industry Watch  [to 13 June 2020]
:: FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers
June 12, 2020

:: Moderna Advances Late-Stage Development of its Vaccine (mRNA-1273) Against COVID-19
June 11, 2020

:: Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July
Jun 10, 2020, 10:00 ET

*  *  *  *  *

Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

American Journal of Infection Control
American Journal of Preventive Medicine
June 2020 Volume 58, Issue 6, p757-898
http://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
June 2020 110(6)
http://ajph.aphapublications.org/toc/ajph/current
[Reviewed earlier]

American Journal of Tropical Medicine and Hygiene
Volume 102, Issue 6, June 2020
http://www.ajtmh.org/content/journals/14761645/102/6
Editorials
oa COVID-19: Shining the Light on Africa
Pages: 1145–1148
https://doi.org/10.4269/ajtmh.20-0380

oa COVID-19: Global Health Equity in Pandemic Response
Louise C. Ivers and David A. Walton
Pages: 1149–1150
https://doi.org/10.4269/ajtmh.20-0260

oa COVID-19: The Need for Immunoprevention at Industrial Scale
Scott B. Halstead
Pages: 1151–1151
https://doi.org/10.4269/ajtmh.20-0239

oa An Urgent Need for ”Common Cold Units” to Study COVID-19
Scott B. Halstead
Pages: 1152–1153
https://doi.org/10.4269/ajtmh.20-0246

oa Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19
Catherine E. Oldenburg and Thuy Doan
Pages: 1154–1155
https://doi.org/10.4269/ajtmh.20-0262

oa Ivermectin and COVID-19: Keeping Rigor in Times of Urgency
The discovery of ivermectin’s activity against SARS-CoV-2 gives reason for hope, but off-label and compassionate use requires careful risk–benefit considerations, especially in critically ill patients. A path to consider is evaluation first of impacts on virologic outcomes in uncomplicated, low-risk patients early in the course of the disease. Well-conducted clinical trials informed by robust pharmacokinetic models should be considered to validate the impact before the use of ivermectin to treat SARS-CoV-2 is implemented.

**Perspective Pieces**

- **Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings**
  Pascale M. Abena, Eric H. Decloedt, Emmanuel Bottieau, Fatima Suleman, Prisca Adejumo, Nadia A. Sam-Agudu, Jean-Jacques Muyembe TamFum, Moussa Seydi, Serge P. Eholie, Edward J. Mills, Oscar Kallay, Alimuddin Zumla and Jean B. Nachega
  Pages: 1184–1188
  https://doi.org/10.4269/ajtmh.20-0290

- **“Global Health”: Time to Refocus while We still Have Time**
  David Bell and Eliah Aronoff-Spencer
  Pages: 1175–1177
  https://doi.org/10.4269/ajtmh.20-0081

- **Reflections on Resilience during the COVID-19 Pandemic: Six Lessons from Working in Resource-Denied Settings**
  Leah Ratner, Rachel Martin-Blais, Clare Warrell and Nirmala P. Narla
  Pages: 1178–1180
  https://doi.org/10.4269/ajtmh.20-0274

**Annals of Internal Medicine**

2 June 2020 Volume 172, Issue 11
http://annals.org/aim/issue
[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 285 August 2020

*Editorial* Abstract only

**Special issue on autonomous agents modelling other agents: Guest editorial**
Stefano V. Albrecht, Peter Stone, Michael P. Wellman
Article 103292

Abstract

Much research in artificial intelligence is concerned with enabling autonomous agents to reason about various aspects of other agents (such as their beliefs, goals, plans, or decisions) and to utilise such reasoning for effective interaction. This special issue contains new technical
contributions addressing open problems in autonomous agents modelling other agents, as well as research perspectives about current developments, challenges, and future directions.

**BMC Cost Effectiveness and Resource Allocation**
http://resource-allocation.biomedcentral.com/
(Accessed 13 June 2020)
[No new digest content identified]

**BMJ Global Health**
June 2020 - Volume 5 - 6
https://gh.bmj.com/content/5/6
[Reviewed earlier]

**BMC Health Services Research**
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 13 June 2020)
[No new digest content identified]

**BMC Infectious Diseases**
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 13 June 2020)
[No new digest content identified]

**BMC Medical Ethics**
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 13 June 2020)

*Research article*

**A qualitative study on aspects of consent for genomic research in communities with low literacy**

Authors: Daima Bukini, Columba Mbekenga, Siana Nkya, Lisa Purvis, Sheryl McCurdy, Michael Parker and Julie Makani

Content type: Research article
12 June 2020

Background

Low literacy of study participants in Sub - Saharan Africa has been associated with poor comprehension during the consenting process in research participation. The concerns in comprehension are far greater when consenting to participate in genomic studies due to the complexity of the science involved. While efforts are made to explore possibilities of applying genomic technologies in diseases prevalent in Sub Saharan Africa, we ought to develop methods to improve participants’ comprehension for genomic studies. The purpose of this study was to understand different approaches that can be used to seek consent from individuals with low literacy in Sub-Saharan African countries in genomic research to improve comprehension.
**BMC Medicine**

http://www.biomedcentral.com/bmcmed/content

(Accessed 13 June 2020)

**Estimating the contribution of different age strata to vaccine serotype pneumococcal transmission in the pre vaccine era: a modelling study**

Herd protection through interruption of transmission has contributed greatly to the impact of pneumococcal conjugate vaccines (PCVs) and may enable the use of cost-saving reduced dose schedules. To aid PCV age...

Authors: Stefan Flasche, Marc Lipsitch, John Ojal and Amy Pinsent
Citation: BMC Medicine 2020 18:129
Content type: Research article
Published on: 10 June 2020

**BMC Pregnancy and Childbirth**

http://www.biomedcentral.com/bmcpregnancychildbirth/content

(Accessed 13 June 2020)

[No new digest content identified]

**BMC Public Health**

http://bmcpublichealth.biomedcentral.com/articles

(Accessed 13 June 2020)

**High level of vaccination and protection against hepatitis B with low rate of HCV infection markers among hospital health care personnel in north of Iran: a cross-sectional study**

hepatitis B virus (HBV) and C virus (HCV) are among the leading causes of mortality worldwide. Health care personnel (HCP) are subjected to increased risk of these infections. Therefore, HBV vaccination and po...

Authors: Saffar Hiva, Khoshayand Negar, Parsaei Mohammad-Reza, Ghorbani Gholam-Reza, Aarabi Mohsen, Nadi Ghara Ali-Asghar and Saffar Mohammed-Jafar
Citation: BMC Public Health 2020 20:920
Content type: Research article
Published on: 12 June 2020

**Timely completion of vaccination and its determinants among children in northwest, Ethiopia: a multilevel analysis**

Timely vaccination is key to prevent unnecessary childhood mortality from vaccine-preventable diseases. Despite the substantial efforts to improve vaccination completeness, the effort towards timeliness of vac...

Authors: Zeleke Abebaw Mekonnen, Kassahun Alemu Gelaye, Martin C. Were and Binyam Tilahun
Citation: BMC Public Health 2020 20:908
Content type: Research article
Published on: 11 June 2020
Use of Real-world Data for New Drug Applications and Line Extensions
Winona R. Bolislis, Myriam Fay, Thomas C. Kühler
p926–938
Published online: April 24, 2020

Purpose
For this article, the authors compiled, summarized, and analyzed data from 27 cases in which real-world data (RWD) were applied in regulatory approval. The aims were to provide an overview of RWD, based on classifications per therapeutic area, age group, drivers of acceptability, utility, data sources, and timelines, and to present insights on how it has been applied in regulatory decision making to date.
Conflict and Health
http://www.conflictandhealth.com/
[Accessed 13 June 2020]
[No new digest content identified]

Contemporary Clinical Trials
Volume 92  May 2020
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/92/suppl/C
[Reviewed earlier]

The CRISPR Journal
Volume 3, Issue 2 / April 2020
https://www.liebertpub.com/toc/crispr/3/2
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 8, Issue 2, June 2020
https://link.springer.com/journal/40142/8/2
[Reviewed earlier]

Current Opinion in Infectious Diseases
June 2020 - Volume 33 - Issue 3
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Developing World Bioethics
Volume 20, Issue 1  Pages: 1-60  March 2020
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 30, Issue 3, 2020
http://www.tandfonline.com/toc/cdip20/current
[New issue; No digest content identified]

Disaster Medicine and Public Health Preparedness
Volume 14 - Issue 2 - April 2020
Disasters
Volume 44, Issue 3  Pages: 433-618  July 2020
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 21  Issue 6  4 June 2020
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 26, Number 6—June 2020
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 31  June 2020
https://www.sciencedirect.com/journal/epidemics/vol/31/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 148 - 2020
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 42, Issue 3  Pages: 1-44  May–June 2020
https://onlinelibrary.wiley.com/toc/25782363/current
Perspectives of minors and parents • Non-English speakers • Covid-19 and other infectious diseases
[Reviewed earlier]

The European Journal of Public Health
Volume 30, Issue 3, June 2020
https://academic.oup.com/eurpub/issue/30/3
Child and adolescent health
Parental education associated with immune function in adolescence
European Union initiatives in child immunization—the need for child centricity, e-health and holistic delivery
Michael J Rigby, Catherine E Chronaki, Shalmali S Deshpande, Peter Altorjai, Maria Brenner ...
https://doi.org/10.1093/eurpub/ckz199

Infectious diseases
How do Twitter users react to TV broadcasts dedicated to vaccines in Italy?
Francesco Gesualdo, Angelo D’Ambrosio, Eleonora Agricola, Luisa Russo, Ilaria Campagna ...
https://doi.org/10.1093/eurpub/ckaa022

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 13 June 2020]
[No new digest content identified]

Genome Medicine
https://genomemedicine.biomedcentral.com/articles
[Accessed 13 June 2020]
[No new digest content identified]

Global Health Action
Volume 12, 2019 Issue 1
https://www.tandfonline.com/toc/zgha20/12/sup1?nav=tocList
[Reviewed earlier]

Global Health: Science and Practice (GHSP)
2020 | Volume 8 | Number 2
http://www.ghspjournal.org/content/current
EDITORIAL COMMENTARY
Will the Higher-Income Country Blueprint for COVID-19 Work in Low- and Lower Middle-Income Countries?
Stephen Hodgins,a Abdulmumin Saadb
Key Message
Strategies currently pursued in high-income and upper middle-income countries—aimed at radically suppressing incidence of COVID-19—may be unrealistic and counterproductive in most low- and lower middle-income countries. Instead, strategies need to be tailored to the setting, balancing expected benefits, potential harms, and feasibility.
From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?

It is often said that it takes 17 years to move medical research from bench to bedside. In a coronavirus disease (COVID-19) world, such time-lags feel intolerable. In these extraordinary circumstances could ye...

Authors: Stephen R. Hanney, Steven Wooding, Jon Sussex and Jonathan Grant
**Humanitarian Exchange Magazine**
Number 77, March 2020

**Responding to Ebola in the Democratic Republic of Congo**
by Humanitarian Practice Network

This edition of Humanitarian Exchange, co-edited with Anne Harmer, focuses on the response to the Ebola outbreak in the Democratic Republic of Congo (DRC). Although at the time of publication the outbreak appeared to have ended, over its course it claimed 2,200 lives, with more than 3,300 infected, making this the world’s second largest outbreak ever.

In the lead article, Natalie Roberts reflects on the extent to which humanitarian actors have applied learning from the outbreak in West Africa in 2014–2016. Richard Kojan and colleagues report on the NGO ALIMA’s flexible, patient-centred approach to reducing mortality, Marcela Ascuntar reflects on lessons learned from community feedback and Bernard Balibuno, Emanuel Mbuna Badjonga and Howard Mollett highlight the crucial role faith-based organisations have played in the response. In their article, Theresa Jones, Noé Kasali and Olivia Tulloch outline the work of the Bethesda counselling centre in Beni, which provides support to grieving families. Reflecting on findings from a recent assessment by Translators without Borders, Ellie Kemp describes the challenges involved in providing clear and accessible information on Ebola and the response, and Sung Joon Park and colleagues explain how humane care and treatment can help increase trust and confidence in the response. Stephen Mugamba and his co-authors highlight the importance of community involvement in Ebola research, and Gillian McKay and her co-authors examine the impact of the Ebola outbreak and response on sexual and reproductive health services.

Stacey Mearns, Kiryn Lanning and Michelle Gayer present an Ebola Readiness Roadmap to support NGOs in preparing for an outbreak, while Edward Kumakech, Maurice Sadlier, Aidan Sinnott and Dan Irvine report on a Gap Analysis tool looking at the communication, community engagement and compliance tracking activities that need to be in place before an Ebola vaccine is deployed. Emanuele Bruni and colleagues describe the development of a new monitoring and evaluation framework for strategic response planning. The edition ends with an article by Adelicia Fairbanks, who argues for an acceptance strategy in the DRC to improve security and access for responding agencies.

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 16, Issue 5, 2020
Conclusion

The key issues for increasing the number of vaccinated people worldwide, especially children, is to increase the supply of available vaccines, assure funding and affordability for lower-income countries, improve distribution and storage networks, assure the availability of healthcare workers to administer vaccines, improve the ability of the population to access vaccination centers, and minimize refusal / hesitation to maximize acceptability of vaccines.

It is noteworthy that among these key issues, all involve physical activities except for the final issue, which is the subject of this Special Issue. Vaccine acceptance / hesitation / refusal is unique in being a state of mind for the potential vaccinee or caregiver, such that different methods must be applied to improve acceptability. The ability of workers in the field to improve acceptability will be directly reflected in increased vaccinations with concomitant reductions in morbidity and mortality from vaccine-preventable diseases. This is a major public health challenge for the coming decade and beyond, which also will be very important for the success of new vaccines in the development pipeline.

This Special Issue includes an extensive number of articles around this theme which we recommend be reviewed.
**International Journal of Epidemiology**
Volume 49, Issue Supplement_1, April 2020
https://academic.oup.com/ije/issue/49/Supplement_1

*Big Data, Small Area*
[Reviewed earlier]

**International Journal of Human Rights in Healthcare**
Volume 13 Issue 2 2020
https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/2

*Special Issue: Sex trafficking and violence against women*
[Reviewed earlier]

**International Journal of Infectious Diseases**
May 2020 Volume 94, p1-164
https://www.ijidonline.com/issue/S1201-9712(20)X0006-3
[Reviewed earlier]

**JAMA**
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

*Research Letter*

**SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults**
Uri Hamiel, MD; Eran Kozer, MD; Ilan Youngster, MD, MMSc
free access has active quiz

This cohort study compares rates of coronavirus PCR test positivity among Israelis with symptoms suspicious for COVID-19 who did and did not receive BCG vaccination as part of routine childhood immunization in the early 1980s.

*Viewpoint*

**COVID-19: Beyond Tomorrow**

**The Ethics of COVID-19 Immunity-Based Licenses (“Immunity Passports”)**
Govind Persad, JD, PhD; Ezekiel J. Emanuel, MD, PhD
free access has active quiz has multimedia has audio

This Viewpoint explains the ethical basis for implementing immunity-based licensing—certification of coronavirus immunity as a basis for permitting public activities—and anticipates challenges to effective implementing such a system, and potential solutions.

Audio Interview: Immunity Passports in the Time of COVID-19

COVID-19: Beyond Tomorrow

**Privileges and Immunity Certification During the COVID-19 Pandemic**
Mark A. Hall, JD; David M. Studdert, LLB, ScD
free access has active quiz
This Viewpoint explains the ethics of implementing licensing or certification of coronavirus immunity as basis for permitting public activities, anticipates challenges to effectively implementing such a system, and proposes potential policy solutions.

COVID-19: Beyond Tomorrow
COVID-19 and Postinfection Immunity -Limited Evidence, Many Remaining Questions
Robert D. Kirkcaldy, MD, MPH; Brian A. King, PhD, MPH; John T. Brooks, MD
free access
This Viewpoint describes what is currently known about the immune response to coronavirus disease 2019 (COVID-19), highlights important gaps in knowledge, and identifies opportunities for future research.

When Should Clinicians Act on Non–Statistically Significant Results From Clinical Trials?
Paul J. Young, PhD, MBChB; Christopher P. Nickson, MBChB; Anders Perner, MD, PhD
has audio
This Viewpoint discusses considerations that might lead physicians to change their practice based on RCTs reporting non–statistically significant differences in primary outcomes, including trial methodology, totality of evidence, cost, invasiveness, and labor-intensiveness of the interventions being compared.
Audio Interview: When Should Physicians Act on Non–Statistically Significant Results From Clinical Trials?

JAMA Pediatrics
June 2020, Vol 174, No. 6, Pages 517-628
http://archpedi.jamanetwork.com/issue.aspx
[Reviewed earlier]

JBI Database of Systematic Review and Implementation Reports
May 2020 - Volume 18 - Issue 5
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx
[Reviewed earlier]

Journal of Adolescent Health
June 2020 Volume 66, Issue 6, p635-766
https://www.jahonline.org/issue/S1054-139X(20)X0004-8
[Reviewed earlier]

Journal of Artificial Intelligence Research
A glossary of theories for understanding power and policy for health equity (20 March, 2020)
Patrick Harris, patrick.harris@unsw.edu.au
Fran Baum, Sharon Friel, Tamara Mackean, Ashley Schram, Bel Townsend

Abstract
Progressing public policies that improve health equity requires understanding and addressing the creation, use and distribution of power. This glossary provides an overview of some of the most relevant conceptualisations of the dynamics of power in policy with implications for health equity. The aim is to provide an accessible overview of the different theories and perspectives behind power for public health focused policy researchers and advocates. The Glossary demonstrates how the broad literature on power in policy deepens understanding of the institutional dynamics that creates and maintains health inequities.
Is There a Correlate of Protection for Measles Vaccine?
Stanley A Plotkin
The Journal of Infectious Diseases, Volume 221, Issue 10, 15 May 2020, Pages 1571–1572,
https://doi.org/10.1093/infdis/jiz381

Our study reviews and evaluates the scientific literature upon which the commonly used 120 mIU/mL measles threshold of protection is based. Our findings suggest that further work is required to characterize the measles immunity threshold.

What Is the Evidence to Support a Correlate of Protection for Measles? A Systematic Review
Shelly Bolotin, Stephanie L Hughes, Nazish Gul, Sumaiya Khan, Paul A Rota ...
The Journal of Infectious Diseases, Volume 221, Issue 10, 15 May 2020, Pages 1576–1583,
https://doi.org/10.1093/infdis/jiz380
Journal of Patient-Centered Research and Reviews  
Volume 7, Issue 2 (2020)  
https://digitalrepository.aurorahealthcare.org/jpcrr/  
[Reviewed earlier]

Journal of Pediatrics  
June 2020 Volume 221, p1-268  
http://www.jpeds.com/current  
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice  
https://joppp.biomedcentral.com/  
[Accessed 13 June 2020]  
[No new digest content identified]

Journal of Public Health Management & Practice  
May/June 2020 - Volume 26 - Issue 3  
https://journals.lww.com/jphmp/pages/currenttoc.aspx  
[Reviewed earlier]

Journal of Public Health Policy  
Volume 41, Issue 2, June 2020  
https://link.springer.com/journal/41271/41/2  
[Reviewed earlier]

Journal of Refugee & Global Health  
https://ir.library.louisville.edu/rgh/  
[Reviewed earlier]

Journal of the Royal Society – Interface  
June 2020 Volume 17 Issue 167  
https://royalsocietypublishing.org/toc/rsif/current  
[New issue; No digest content identified]

Journal of Travel Medicine  
Volume 27, Issue 3, April 2020  
https://academic.oup.com/jtm/issue/27/3  
[Reviewed earlier]
The Lancet
Jun 13, 2020  Volume 395  Number 10240  p1813-1882, e102-e106
https://www.thelancet.com/journals/lancet/issue/current

Comment
The WHO we want
Olivier Nay, Marie-Paule Kieny, Lelio Marmora, Michel Kazatchkine

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
The Lancet Editors

World Report
COVID-19 vaccines for all?
Ann Danaiya Usher

Articles
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
Feng-Cai Zhu, et al,

Interpretation
The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination. Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination. Our findings suggest that the Ad5 vectored COVID-19 vaccine warrants further investigation.

The Lancet Child & Adolescent Health
Jun 2020  Volume 4  Number 6  p407-478, e12-e16
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Jun 2020  Volume 2  Number 6e268-e330
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
The online competition between pro- and anti-vaccination views
Insights into the interactions between pro- and anti-vaccination clusters on Facebook can enable policies and approaches that attempt to interrupt the shift to anti-vaccination views and persuade undecided individuals to adopt a pro-vaccination stance.

Neil F. Johnson, Nicolas Velásquez[...] & Yonatan Lupu

**Nature Biotechnology**
Volume 38 Issue 6, June 2020
[https://www.nature.com/nbt/volumes/38/issues/6](https://www.nature.com/nbt/volumes/38/issues/6)
*Editorial* | 03 June 2020
**The COVID-19 testing debacle**
Insufficient SARS-CoV-2 testing has left many nations flying blind as they reopen their economies. Without adequate testing, new infections could outrun control measures.

**Nature Communications**
[https://www.nature.com/subjects/health-sciences/ncomms](https://www.nature.com/subjects/health-sciences/ncomms)
(Accessed 13 June 2020)
[No new digest content identified]

**Nature Genetics**
Volume 52 Issue 6, June 2020
[Reviewed earlier]

**Nature Medicine**
Volume 26 Issue 5, May 2020
[https://www.nature.com/nm/volumes/26/issues/5](https://www.nature.com/nm/volumes/26/issues/5)
[Reviewed earlier]

**Nature Reviews Genetics**
Volume 21 Issue 6, June 2020
[https://www.nature.com/nrg/volumes/21/issues/6](https://www.nature.com/nrg/volumes/21/issues/6)
[Reviewed earlier]

**Nature Reviews Immunology**
Volume 20 Issue 6, June 2020
[Reviewed earlier]

**Nature Reviews Drug Discovery**
Volume 19 Issue 6, June 2020
[Reviewed earlier]
New England Journal of Medicine
June 11, 2020 Vol. 382 No. 24
http://www.nejm.org/toc/nejm/medical-journal

Perspective
The Vaccines for Children Program at 25 — Access, Affordability, and Sustainability
Jason L. Schwartz, Ph.D., and James Colgrove, Ph.D., M.P.H.

The success of the Vaccines for Children program has meant that vaccine costs are seldom a major obstacle to childhood-vaccination efforts. But the program’s financial sustainability and the implications of its growth for other public health priorities are key issues.

Perspective
Drug Evaluation during the Covid-19 Pandemic
Benjamin N. Rome, M.D., and Jerry Avorn, M.D.

The search for a treatment for Covid-19 is testing our country’s ability to quickly develop, test, and deploy medications, presenting both opportunities and challenges to our drug-assessment apparatus. Several aspects of the U.S. response raise serious concerns, highlighting how the processes for evaluating and approving drugs can go awry during a public health crisis...

Original Article
Compassionate Use of Remdesivir for Patients with Severe Covid-19
Jonathan Grein, M.D., et al.

Abstract
Background
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2.

Methods
We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day.

Results
Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation.

Conclusions
In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%).
Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)

**Pediatrics**  
Jun 2020, 145 (6)  
[Reviewed earlier]

**Pharmaceutics**  
Volume 12, Issue 5 (May 2020)  
[Reviewed earlier]

**PharmacoEconomics**  
Volume 38, Issue 5, May 2020  
[Reviewed earlier]

**PLoS Genetics**  
https://journals.plos.org/plosgenetics/  
(Accessed 13 June 2020)  
[No new digest content identified]

**PLoS Medicine**  
http://www.plosmedicine.org/  
(Accessed 13 June 2020)  
*Social determinants of health, data science, and decision-making: Forging a transdisciplinary synthesis*  
Sandro Galea, Salma M. Abdalla, Jeffrey L. Sturchio  
Perspective | published 11 Jun 2020 PLOS Medicine  
https://doi.org/10.1371/journal.pmed.1003174

**PLoS Neglected Tropical Diseases**  
http://www.plosntds.org/  
(Accessed 13 June 2020)  
*Inclusion of women susceptible to and becoming pregnant in preregistration clinical trials in low- and middle-income countries: A proposal for neglected tropical diseases*  
Monique Couderc-Petry, Elisabeth Eléfant, Monique Wasunna, Alwyn Mwinga, Nilima A. Kshirsagar, Nathalie Strub-Wourgaft  
Policy Platform | published 11 Jun 2020 PLOS Neglected Tropical Diseases  
https://doi.org/10.1371/journal.pntd.0008140
Video as a public health knowledge transfer tool in Burkina Faso: A mixed evaluation comparing three narrative genres
Catherine Hébert, Christian Dagenais, Esther Mc Sween-Cadieux, Valéry Ridde
Research Article | published 10 Jun 2020 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0008305

PLoS One
http://www.plosone.org/
[Accessed 13 June 2020]
[No new digest content identified]

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 13 June 2020]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States of America
http://www.pnas.org/content/early/
[No new digest content identified]

Prehospital & Disaster Medicine
Volume 35 - Issue 3 - June 2020
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 135  June 2020
[Reviewed earlier]

Proceedings of the Royal Society B
10 June 2020  Volume 287  Issue 1928
https://royalsocietypublishing.org/toc/rspb/current
[No new digest content identified]

Public Health
Volume 183  Pages 1-152 (June 2020)
[New issue; No digest content identified]
Monitoring inequality changes in full immunization coverage in infants in Latin America and the Caribbean

Full immunization coverage in the countries in the study shows higher-income inequality gaps that are not seen by observing national coverage only, but these differences appear to be reduced over time. Actions monitoring immunization coverage based on income inequalities should be considered for inclusion in the assessment of public health policies to appropriately reduce the gaps in immunization for infants in the lowest-income quintile.
**Risk Management and Healthcare Policy**
[Reviewed earlier]

**Science**
12 June 2020 Vol 368, Issue 6496
http://www.sciencemag.org/current.dtl

*Editorial*
**COVID-19 and flu, a perfect storm**
By Edward A. Belongia, Michael T. Osterholm

*Summary*
The world is in uncharted waters for the 2020 respiratory virus season. For the first time in modern history, the Northern Hemisphere faces the prospect of the coronavirus disease 2019 (COVID-19) pandemic and a simultaneous epidemic of seasonal influenza. Each causes life-threatening illness and death, especially in older adults, people with chronic diseases, and other vulnerable populations. How can we prepare for this convergence?

*In Depth*
**Vaccines that use human fetal cells draw fire**
By Meredith Wadman
Science12 Jun 2020 : 1170-1171 Full Access

*Summary*
Abortion opponents urge United States and Canada to avoid "ethically-tainted" cell lines.

Senior Catholic leaders in the United States and Canada, along with other antiabortion groups, are raising ethical objections to promising COVID-19 vaccine candidates that are manufactured using cells derived from human fetuses electively aborted decades ago. They have not sought to block government funding for the vaccines, which include two candidate vaccines that the Trump administration plans to support with an investment of up to $1.7 billion, as well as a third candidate made by a Chinese company in collaboration with Canada’s National Research Council. But in recent letters they implore the U.S. Food and Drug Administration and Canadian Prime Minister Justin Trudeau to ensure that alternatives that don’t rely on fetal cells are made available.

**Science Translational Medicine**
10 June 2020 Vol 12, Issue 547
https://stm.sciencemag.org/
[New issue; No digest content identified]

**Social Science & Medicine**
Volume 252 May 2020
[Reviewed earlier]
Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 13 June 2020]
[No digest content identified]

Travel Medicine and Infectious Diseases
Volume 34 March–April 2020
[Reviewed earlier]

Tropical Medicine & International Health
Volume 25, Issue 6 Pages: i-iv, 645-750 June 2020
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 38, Issue 27
Pages 4219-4354 (2 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/27
Editorial  Full text access
Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development
Gregory A. Poland
Pages 4219-4220

Research article  Abstract only
Barriers and drivers to adult vaccination among family physicians – Insights for tailoring the immunization program in Germany
Julia Neufeind, Cornelia Betsch, Katrine Bach Habersaat, Matthias Eckardt, ... Ole Wichmann
Pages 4252-4262

Research article  Open access
A single dose of quadrivalent human papillomavirus (HPV) vaccine is immunogenic and reduces HPV detection rates in young women in Mongolia, six years after vaccination
Tsetsegsaihan Batmunkh, Marguerite T. Dalmau, Margad-Erdene Munkhsaikhan, Tungalagtuya Khorolsuren, ... Claire von Mollendorf
Pages 4316-4324

Research article  Abstract only
Intent to obtain pediatric influenza vaccine among mothers in four middle income countries
Abram L. Wagner, Aubree Gordon, Veronica L. Tallo, Artan Simaku, ... Mark G. Thompson
Vaccine
Volume 38, Issue 26
Pages 4135-4218 (27 May 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/26
Research article  Full text access
Enabling emergency mass vaccination: Innovations in manufacturing and administration during a pandemic
Divya Hosangadi, Kelsey Lane Warmbrod, Elena K. Martin, Amesh Adalja, ... Nancy Connell
Pages 4167-4169

Research article  Abstract only
Archetype analysis of older adult immunization decision-making and implementation in 34 countries
Lois Privor-Dumm, Prarthana Vasudevan, Kana Kobayashi, Jaya Gupta
Pages 4170-4182

Research article  Abstract only
Vaccine indicator and reminder band to improve demand for vaccination in Northern Nigeria: A qualitative evaluation of implementation outcomes
Chisom Obi-Jeff, Noor Sabah Rakhshani, Jamila Ibiye Bello-Malabu, Chike Nwangwu, ... Chizoba Wonodi
Pages 4191-4199

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 13 June 2020)
Open Access  Article
Coverage and Timeliness of Birth Dose Vaccination in Sub-Saharan Africa: A Systematic Review and Meta-Analysis
by Oumar Bassoum, Moe Kimura, Anta Tal Dia, Maud Lemoine and Yusuke Shimakawa
Vaccines 2020, 8(2), 301; https://doi.org/10.3390/vaccines8020301 - 11 Jun 2020
Abstract
Background: Depending on the epidemiological context of each country, three vaccines are recommended by the World Health Organization (WHO) to be administered as soon as possible after birth (birth vaccines); namely, BCG, zero dose of oral polio vaccine (OPV0), and birth dose

Open Access  Article
Influenza Vaccination Experiences of Pregnant Women as a Predictor of the Intention to Become Vaccinated in Future Pregnancies in Spain
by Noelia Rodríguez-Blanco, José Tuells and Andreu Nolasco
Vaccines 2020, 8(2), 291; https://doi.org/10.3390/vaccines8020291 - 09 Jun 2020
Viewed by 256
Abstract
A good perception of the vaccines administered during pregnancy favors immunization coverage, which is still not optimal for the influenza vaccine. To understand the predisposition
towards vaccination in future pregnancies, a study was performed that evaluated the experiences of women with the vaccine.

**Value in Health**  
May 2020 Volume 23, Issue 5, p527-676  
https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0006-4  
**THEMED SECTION: PRECISION MEDICINE**  
[Reviewed earlier]

* * * * *

**From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary**

No new digest content identified.

* * * * *

**Media/Policy Watch**  
This watch section is intended to alert readers to substantive news, analysis and opinion from the general media and selected think tanks and similar organizations on vaccines, immunization, global public health and related themes. *Media Watch* is not intended to be exhaustive, but indicative of themes and issues CVEP is actively tracking. This section will grow from an initial base of newspapers, magazines and blog sources, and is segregated from *Journal Watch* above which scans the peer-reviewed journal ecology.

We acknowledge the Western/Northern bias in this initial selection of titles and invite suggestions for expanded coverage. We are conservative in our outlook in adding news sources which largely report on primary content we are already covering above. Many electronic media sources have tiered, fee-based subscription models for access. We will provide full-text where content is published without restriction, but most publications require registration and some subscription level.

**The Atlantic**  
http://www.theatlantic.com/magazine/  
*Accessed 13 June 2020*

**Health**  
**Coronavirus Researchers Tried to Warn Us**  
*Before the pandemic hit, they struggled to get funding that might have hastened treatments for COVID-19.*  
Charles Schmidt and Undark

The now-prophetic words could be found at the end of a research paper published in the journal Clinical Microbiology Reviews in October of 2007: “The presence of a large reservoir of
SARS-CoV-like viruses in horseshoe bats, together with the culture of eating exotic mammals in southern China, is a time bomb.”

The warning—made nearly 13 years ago and more than four years after the worrying first wave of severe acute respiratory syndrome, or SARS, killed nearly 800 people globally—was among the earliest to predict the emergence of something like SARS-CoV-2, the virus behind the current COVID-19 pandemic.

Many other warnings would follow...

**Ideas**

**The Virus Will Win**

Americans are pretending that the pandemic is over. It certainly is not.

June 12, 2020

Yascha Mounk, Contributing writer at The Atlantic

A second wave of the coronavirus is on the way. When it arrives, we will lack the will to deal with it. Despite all the sacrifices of the past months, the virus is likely to win—or perhaps it would be more accurate to say that it already has.

In absolute terms, the United States has been hit harder than any other country. About a quarter of worldwide deaths have been recorded on these shores. And while the virus is no longer growing at an exponential rate, the threat it poses remains significant: According to a forecasting model by Morgan Stanley, the number of American cases will, if current trends hold, roughly double over the next two months.

But neither the impact of mass protests over police brutality nor the effect of the recent reopening of much of the country—including the casinos in Las Vegas—is reflected in the latest numbers. It can take at least 10 days for people to develop symptoms and seek out a test, and for the results to be aggregated and disseminated by public-health authorities.

Even so, the disease is slowly starting to recede from the public’s attention. After months of dominating media coverage, COVID-19 has largely disappeared from the front pages of most national newspapers. In recent polls, the number of people who favor “reopening the economy as soon as possible” over “staying home as long as necessary” has increased. And so it is perhaps no surprise that even states where the number of new infections stands at an all-time high are pressing ahead with plans to lift many restrictions on businesses and mass gatherings...

**BBC**

http://www.bbc.co.uk/

*Accessed 13 June 2020*

[No new, unique, relevant content]

**The Economist**

http://www.economist.com/

*Accessed 13 June 2020*

[No new, unique, relevant content]

**Financial Times**

http://www.ft.com/home/uk

*Coronavirus pandemic*

**Covid-19 cases spike in several US states | DC Lockdown Diary**
June 13, 2020

*Coronavirus pandemic*

OECD warns of deepest economic scars in peacetime for a century

June 10, 2020

*Coronavirus pandemic*

Anthony Fauci warns pandemic has further to run

June 9, 2020

**Forbes**


Accessed 13 June 2020

Jun 12, 2020

**The Hideous Truths Of Testing Vaccines On Humans**

Sixty years ago, a monstrous hepatitis experiment was performed on mentally disabled children at Willowbrook State School that raises serious ethical questions about vaccine challenge trials for Covid-19.

By [Leah Rosenbaum](http://www.forbes.com) Forbes Staff

Jun 12, 2020

**Coronavirus Vaccine Options Would Help The Economy**

Corporations with cash who would benefit greatly from a vaccine should use their resources to speed development. Buying vaccine options would do that.

By [Bill Conerly](http://www.forbes.com) Senior Contributor

**Foreign Affairs**


Accessed 13 June 2020

Snapshot June 13, 2020

**Democracy Versus the Pandemic**

The downward democratic spiral can still be reversed, but it will require mobilized civil societies, effective democratic management of the health crisis, and a renewal...

Larry Diamond

*Comment* July/August 2020

**When the System fails**

The pandemic has revealed both the limits of the existing multilateral system and the horrific costs of the system’s failure.

Stewart Patrick

**Foreign Policy**


Accessed 13 June 2020 | [No new, unique, relevant content] [No new, unique, relevant content]

**The Guardian**


June 13, 2020
Fauci says US might not see 'second wave' of Covid-19 cases ...

New Yorker
http://www.newyorker.com/
Accessed 13 June 2020
U.S. Journal
Can Coronavirus Contact Tracing Survive Reopening?
Massachusetts created a pioneering program to track COVID-19 cases. Its challenges are multiplying as the state reopens.
By Benjamin Wallace-Wells
June 12, 2020

Daily Comment
What the W.H.O. Meant to Say About Asymptomatic People Spreading the Coronavirus
The W.H.O. official’s words were terribly misleading, but the organization quickly clarified that social distancing and masks are not just for those who clearly have symptoms.
By Amy Davidson Sorkin
June 11, 2020

New York Times
http://www.nytimes.com/
Accessed 13 June 2020
Sunday Review
Don’t Leave the W.H.O. Strengthen It.
The organization is still the world’s best hope for fighting pandemics.
By The Editorial Board  June 13, 2020

Science
Guaranteed Ingredient in Any Coronavirus Vaccine? Thousands of Volunteers
Two sisters in Missouri were among the first to have an unproven coronavirus vaccine injected in their bodies. If it makes it to market, it would also be the first DNA vaccine for any disease.
By Heather Murphy  June 13, 2020

Business
AstraZeneca Agrees to Make COVID-19 Vaccine for Europe
Drugmaker AstraZeneca struck a deal Saturday to supply up to 400 million doses of an experimental COVID-19 vaccine to European Union countries, the latest in a series of agreements as scientists, governments and pharmaceutical companies race to combat the virus.
By The Associated Press  June 13, 2020

World
Coronavirus Live Updates: Chile’s Health Minister Resigns Amid Criticism
China closed a market that handles 90 percent of Beijing’s fresh fruit and vegetables after dozens of people tested positive. Florida sees a record number of new cases for the third day in a row.
Opinion

Could Trump Turn a Vaccine Into a Campaign Stunt?

In a desperate search for a boost, he could release a coronavirus vaccine that has not been shown to be safe and effective as an October surprise.

By Ezekiel J. Emanuel and Paul A. Offit

Washington Post

https://www.washingtonpost.com/

Accessed 13 June 2020

Can old vaccines from science’s medicine cabinet ward off coronavirus?

Carolyn Y. Johnson and Steven Mufson · Health · Jun 11, 2020

* * * * *

Think Tanks et al

Brookings

http://www.brookings.edu/

Accessed 13 June 2020

Op-Ed

COVID-19 may ultimately strengthen Latin America’s democracies, not destroy them

Eduardo Levy Yeyati and Andrés Malamud

Thursday, June 11, 2020

Global Economy

Less globalization, more multilateralism

Kemal Derviş

Wednesday, June 10, 2020

Center for Global Development

http://www.cgdev.org/page/press-center

Accessed 13 June 2020

June 12, 2020

Evidence-Based Decision Making During COVID-19: How to Navigate Extreme Uncertainty and Urgency

Evidence-based policy generation is an aspiration more than reality at the best of times. With COVID-19 generating extreme uncertainty and urgency of action across the world, it has become harder than ever. This blog considers three areas where both researchers and policymakers need to engage more effectively: asking better questions; being clearer about how well we can answer them; and broadening collaboration and challenge.

Ranil Dissanayake

June 9, 2020
What Does Success Look Like for a COVID-19 Vaccine? Improving Portfolio Level Understanding

Around the world COVID-19 and the policy responses to it are causing unprecedented disruptions of life and wellbeing. As scientists and governments around the world race to develop a vaccine at scale, we take a look at what a portfolio approach entails and why it is so important.

Anthony McDonnell, Prashant Yadav and Kalipso Chalkidou

June 8, 2020

In the Race to Develop a Vaccine For COVID-19, Is a Pull for R&D Essential or Optional?

The global race to develop a COVID-19 vaccine is far from conventional. An effective vaccine would offer one of the few credible exit paths from the world’s worst public health and economic crisis in recent history. Is a pull for R&D essential or optional?

Kalipso Chalkidou et al.

Chatham House [to 13 June 2020]
https://www.chathamhouse.org/
[No new relevant content]

CSIS
https://www.csis.org/
Accessed 13 June 2020
[No new relevant content]

Council on Foreign Relations
http://www.cfr.org/
Accessed 13 June 2020
[No new relevant content]

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
Accessed 13 June 2020
[No new relevant content]

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/). Copyright is retained by CVEP.
CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances. CVEP maintains an academic affiliation with the Division of Medical Ethics, NYU School of Medicine, and an operating affiliation with the Vaccine Education Center of Children’s Hospital of Philadelphia [CHOP].

Support for this service is provided by the Bill & Melinda Gates Foundation; PATH, and industry resource members Janssen/J&J, Pfizer, Sanofi Pasteur U.S., Takeda, Moderna Therapeutics (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.